Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Ga68-labeled Fibroblast Activation Protein Inhibitor-46 (Ga68-FAPI-46) PET/CT for Preoperative Assessment of Peritoneal Carcinomatosis

NCT06061874 is registered in ClinicalTrials.gov with Jules Bordet Institute as lead sponsor.

NCT NCT06061874
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06061874 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Ga68-labeled Fibroblast Activation Protein Inhibitor-46 (Ga68-FAPI-46) PET/CT for Preoperative Assessment of Peritoneal Carcinomatosis
Lead sponsor
Jules Bordet Institute
Phase
Not applicable
Overall status
Recruiting
Start date
May 30, 2023
Completion date
December 31, 2025
Enrollment
80 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, peritoneal carcinomatosis